Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Environmental Exposures Such as Smoking and Low Vitamin D Are Predictive of Poor Outcome in Cutaneous Melanoma rather than Other Deprivation Measures.

Hardie CM, Elliott F, Chan M, Rogers Z, Bishop DT, Newton-Bishop JA.

J Invest Dermatol. 2020 Feb;140(2):327-337.e2. doi: 10.1016/j.jid.2019.05.033. Epub 2019 Aug 16.

PMID:
31425707
2.

High-Resolution Copy Number Patterns From Clinically Relevant FFPE Material.

Filia A, Droop A, Harland M, Thygesen H, Randerson-Moor J, Snowden H, Taylor C, Diaz JMS, Pozniak J, Nsengimana J, Laye J, Newton-Bishop JA, Bishop DT.

Sci Rep. 2019 Jun 20;9(1):8908. doi: 10.1038/s41598-019-45210-2.

3.

Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure.

Cust AE, Drummond M, Bishop DT, Azizi L, Schmid H, Jenkins MA, Hopper JL, Armstrong BK, Aitken JF, Kefford RF, Giles GG, Demenais F, Goldstein AM, Barrett JH, Kanetsky PA, Elder DE, Mann GJ, Newton-Bishop JA.

J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1874-1885. doi: 10.1111/jdv.15680. Epub 2019 Jun 7.

4.

Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.

Taylor NJ, Mitra N, Qian L, Avril MF, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Goldstein AM, Grazziotin TC, Gruis NA, Hansson J, Harland M, Hayward NK, Hocevar M, Höiom V, Holland EA, Ingvar C, Landi MT, Landman G, Larre-Borges A, Mann GJ, Nagore E, Olsson H, Palmer JM, Perić B, Pjanova D, Pritchard AL, Puig S, Schmid H, van der Stoep N, Tucker MA, Wadt KAW, Yang XR, Newton-Bishop JA, Kanetsky PA; GenoMEL Study Group.

J Am Acad Dermatol. 2019 Aug;81(2):386-394. doi: 10.1016/j.jaad.2019.01.079. Epub 2019 Feb 5.

PMID:
30731170
5.

Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.

Duffy DL, Zhu G, Li X, Sanna M, Iles MM, Jacobs LC, Evans DM, Yazar S, Beesley J, Law MH, Kraft P, Visconti A, Taylor JC, Liu F, Wright MJ, Henders AK, Bowdler L, Glass D, Ikram MA, Uitterlinden AG, Madden PA, Heath AC, Nelson EC, Green AC, Chanock S, Barrett JH, Brown MA, Hayward NK, MacGregor S, Sturm RA, Hewitt AW; Melanoma GWAS Consortium, Kayser M, Hunter DJ, Newton Bishop JA, Spector TD, Montgomery GW, Mackey DA, Smith GD, Nijsten TE, Bishop DT, Bataille V, Falchi M, Han J, Martin NG.

Nat Commun. 2019 Jan 14;10(1):299. doi: 10.1038/s41467-018-08078-w.

6.

Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma.

Wong K, Robles-Espinoza CD, Rodriguez D, Rudat SS, Puig S, Potrony M, Wong CC, Hewinson J, Aguilera P, Puig-Butille JA, Bressac-de Paillerets B, Zattara H, van der Weyden L, Fletcher CDM, Brenn T, Arends MJ, Quesada V, Newton-Bishop JA, Lopez-Otin C, Bishop DT, Harms PW, Johnson TM, Durham AB, Lombard DB, Adams DJ.

JAMA Dermatol. 2019 May 1;155(5):604-609. doi: 10.1001/jamadermatol.2018.3662.

7.

Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.

Duffy DL, Zhu G, Li X, Sanna M, Iles MM, Jacobs LC, Evans DM, Yazar S, Beesley J, Law MH, Kraft P, Visconti A, Taylor JC, Liu F, Wright MJ, Henders AK, Bowdler L, Glass D, Ikram MA, Uitterlinden AG, Madden PA, Heath AC, Nelson EC, Green AC, Chanock S, Barrett JH, Brown MA, Hayward NK, MacGregor S, Sturm RA, Hewitt AW; Melanoma GWAS Consortium, Kayser M, Hunter DJ, Newton Bishop JA, Spector TD, Montgomery GW, Mackey DA, Smith GD, Nijsten TE, Bishop DT, Bataille V, Falchi M, Han J, Martin NG.

Nat Commun. 2018 Nov 14;9(1):4774. doi: 10.1038/s41467-018-06649-5. Erratum in: Nat Commun. 2019 Jan 14;10(1):299.

8.

Assessing the Incremental Contribution of Common Genomic Variants to Melanoma Risk Prediction in Two Population-Based Studies.

Cust AE, Drummond M, Kanetsky PA; Australian Melanoma Family Study Investigators; Leeds Case-Control Study Investigators, Goldstein AM, Barrett JH, MacGregor S, Law MH, Iles MM, Bui M, Hopper JL, Brossard M, Demenais F, Taylor JC, Hoggart C, Brown KM, Landi MT, Newton-Bishop JA, Mann GJ, Bishop DT.

J Invest Dermatol. 2018 Dec;138(12):2617-2624. doi: 10.1016/j.jid.2018.05.023. Epub 2018 Jun 8.

9.

Publisher correction: Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148.

Fang J, Jia J, Makowski M, Xu M, Wang Z, Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, Thomas J, Kovacs M, Collins I, Dzyadyk M, Thompson A, O'Neill M, Das S, Lan Q, Koster R, Stolzenberg-Solomon RS, Kraft P, Wolpin BM, Jansen PWTC, Olson S, McGlynn KA, Kanetsky PA, Chatterjee N, Barrett JH, Dunning AM, Taylor JC, Newton-Bishop JA, Timothy Bishop D, Andresson T, Petersen GM, Amos CI, Iles MM, Nathanson KL, Teresa Landi M, Vermeulen M, Brown KM, Amundadottir LT.

Nat Commun. 2018 Mar 5;9:16159. doi: 10.1038/ncomms16159.

10.

Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing.

Artomov M, Stratigos AJ, Kim I, Kumar R, Lauss M, Reddy BY, Miao B, Daniela Robles-Espinoza C, Sankar A, Njauw CN, Shannon K, Gragoudas ES, Marie Lane A, Iyer V, Newton-Bishop JA, Timothy Bishop D, Holland EA, Mann GJ, Singh T, Daly MJ, Tsao H.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx083.

11.

Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

Taylor NJ, Mitra N, Goldstein AM, Tucker MA, Avril MF, Azizi E, Bergman W, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Grazziotin TC, Hansson J, Harland M, Hayward NK, Hocevar M, Höiom V, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer JM, Perić B, Pjanova D, Pritchard A, Puig S, van der Stoep N, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL Study Group.

J Invest Dermatol. 2017 Dec;137(12):2606-2612. doi: 10.1016/j.jid.2017.07.829. Epub 2017 Aug 19.

12.

A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.

Choi J, Xu M, Makowski MM, Zhang T, Law MH, Kovacs MA, Granzhan A, Kim WJ, Parikh H, Gartside M, Trent JM, Teulade-Fichou MP, Iles MM, Newton-Bishop JA, Bishop DT, MacGregor S, Hayward NK, Vermeulen M, Brown KM.

Nat Genet. 2017 Sep;49(9):1326-1335. doi: 10.1038/ng.3927. Epub 2017 Jul 31.

13.

Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148.

Fang J, Jia J, Makowski M, Xu M, Wang Z, Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, Thomas J, Kovacs M, Collins I, Dzyadyk M, Thompson A, O'Neill M, Das S, Lan Q, Koster R; PanScan Consortium; TRICL Consortium; GenoMEL Consortium, Stolzenberg-Solomon RS, Kraft P, Wolpin BM, Jansen PWTC, Olson S, McGlynn KA, Kanetsky PA, Chatterjee N, Barrett JH, Dunning AM, Taylor JC, Newton-Bishop JA, Bishop DT, Andresson T, Petersen GM, Amos CI, Iles MM, Nathanson KL, Landi MT, Vermeulen M, Brown KM, Amundadottir LT.

Nat Commun. 2017 May 2;8:15034. doi: 10.1038/ncomms15034. Erratum in: Nat Commun. 2018 Mar 05;9:16159.

14.

A population-based analysis of germline BAP1 mutations in melanoma.

O'Shea SJ, Robles-Espinoza CD, McLellan L, Harrigan J, Jacq X, Hewinson J, Iyer V, Merchant W, Elliott F, Harland M, Bishop DT, Newton-Bishop JA, Adams DJ.

Hum Mol Genet. 2017 Feb 15;26(4):717-728. doi: 10.1093/hmg/ddw403.

15.

Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study.

O'Shea SJ, Rogers Z, Warburton F, Ramirez AJ, Newton-Bishop JA, Forbes LJ.

BMC Cancer. 2017 Jan 3;17(1):5. doi: 10.1186/s12885-016-2978-6.

16.

Vitamin D, vitamin A, the primary melanoma transcriptome and survival.

O'Shea SJ, Davies JR, Newton-Bishop JA.

Br J Dermatol. 2016 Oct;175 Suppl 2:30-34. doi: 10.1111/bjd.14919. Review.

17.

Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.

Taylor NJ, Handorf EA, Mitra N, Avril MF, Azizi E, Bergman W, Bianchi-Scarrà G, Bishop DT, Bressac-de Paillerets B, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Friedman E, Gerdes AM, Ghiorzo P, Goldstein AM, Grazziotin TC, Hansson J, Hayward NK, Hocevar M, Höiom V, Holland EA, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer J, Perić B, Pjanova D, Puig S, Schmid H, van der Stoep N, Tucker MA, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL Consortium.

J Invest Dermatol. 2016 May;136(5):1066-1069. doi: 10.1016/j.jid.2016.01.009. Epub 2016 Jan 28. No abstract available.

18.

Histopathology of melanocytic lesions in a family with an inherited BAP1 mutation.

O'Shea SJ, Mitra A, Graham JL, Charlton R, Adlard J, Merchant W, Newton-Bishop JA.

J Cutan Pathol. 2016 Mar;43(3):287-9. doi: 10.1111/cup.12625. Epub 2015 Oct 12. No abstract available.

19.

Germline TERT promoter mutations are rare in familial melanoma.

Harland M, Petljak M, Robles-Espinoza CD, Ding Z, Gruis NA, van Doorn R, Pooley KA, Dunning AM, Aoude LG, Wadt KA, Gerdes AM, Brown KM, Hayward NK, Newton-Bishop JA, Adams DJ, Bishop DT.

Fam Cancer. 2016 Jan;15(1):139-44. doi: 10.1007/s10689-015-9841-9.

20.

Authors' reply to: High naevus counts confer a favourable prognosis in patients with melanoma.

Ribero S, Davies JR, Glass D, Quaglino P, Newton Bishop JA, Nagore E, Puig S, Bataille V.

Int J Cancer. 2015 Dec 15;137(12):3008-9. doi: 10.1002/ijc.29652. Epub 2015 Jul 22. No abstract available.

21.

Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma.

Gao L, van den Hurk K, Nsengimana J, Laye JP, van den Oord JJ, Beck S, Gruis NA, Zoutman WH, van Engeland M, Newton-Bishop JA, Winnepenninckx VJ, van Doorn R.

J Invest Dermatol. 2015 Sep;135(9):2328-2331. doi: 10.1038/jid.2015.163. Epub 2015 Apr 28. No abstract available.

22.

High nevus counts confer a favorable prognosis in melanoma patients.

Ribero S, Davies JR, Requena C, Carrera C, Glass D, Rull R, Vidal-Sicart S, Vilalta A, Alos L, Soriano V, Quaglino P, Traves V, Newton-Bishop JA, Nagore E, Malvehy J, Puig S, Bataille V.

Int J Cancer. 2015 Oct 1;137(7):1691-8. doi: 10.1002/ijc.29525. Epub 2015 Apr 11.

23.

Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.

Aoude LG, Pritchard AL, Robles-Espinoza CD, Wadt K, Harland M, Choi J, Gartside M, Quesada V, Johansson P, Palmer JM, Ramsay AJ, Zhang X, Jones K, Symmons J, Holland EA, Schmid H, Bonazzi V, Woods S, Dutton-Regester K, Stark MS, Snowden H, van Doorn R, Montgomery GW, Martin NG, Keane TM, López-Otín C, Gerdes AM, Olsson H, Ingvar C, Borg A, Gruis NA, Trent JM, Jönsson G, Bishop DT, Mann GJ, Newton-Bishop JA, Brown KM, Adams DJ, Hayward NK.

J Natl Cancer Inst. 2014 Dec 13;107(2). pii: dju408. doi: 10.1093/jnci/dju408. Print 2015 Feb.

24.

25-Hydroxyvitamin D2 /D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort.

Newton-Bishop JA, Davies JR, Latheef F, Randerson-Moor J, Chan M, Gascoyne J, Waseem S, Haynes S, O'Donovan C, Bishop DT.

Int J Cancer. 2015 Jun 15;136(12):2890-9. doi: 10.1002/ijc.29334. Epub 2014 Dec 13.

25.

The effect on melanoma risk of genes previously associated with telomere length.

Iles MM, Bishop DT, Taylor JC, Hayward NK, Brossard M, Cust AE, Dunning AM, Lee JE, Moses EK, Akslen LA; AMFS Investigators, Andresen PA, Avril MF, Azizi E, Scarrà GB, Brown KM, Dębniak T, Elder DE, Friedman E, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Harland M, Helsing P, Hočevar M, Höiom V; IBD investigators, Ingvar C, Kanetsky PA, Landi MT, Lang J, Lathrop GM, Lubiński J, Mackie RM, Martin NG, Molven A, Montgomery GW, Novaković S, Olsson H, Puig S, Puig-Butille JA; QMEGA and QTWIN Investigators, Radford-Smith GL, Randerson-Moor J; SDH Study Group, van der Stoep N, van Doorn R, Whiteman DC, MacGregor S, Pooley KA, Ward SV, Mann GJ, Amos CI, Pharoah PD, Demenais F, Law MH, Newton Bishop JA, Barrett JH; GenoMEL Consortium.

J Natl Cancer Inst. 2014 Sep 17;106(10). pii: dju267. doi: 10.1093/jnci/dju267. Print 2014 Oct.

26.

Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma.

Molassiotis A, Brunton L, Hodgetts J, Green AC, Beesley VL, Mulatero C, Newton-Bishop JA, Lorigan P.

Ann Oncol. 2014 Oct;25(10):2052-8. doi: 10.1093/annonc/mdu366. Epub 2014 Jul 31.

27.

Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions.

Barrett JH, Taylor JC, Bright C, Harland M, Dunning AM, Akslen LA, Andresen PA, Avril MF, Azizi E, Bianchi Scarrà G, Brossard M, Brown KM, Dębniak T, Elder DE, Friedman E, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Helsing P, Hočevar M, Höiom V, Ingvar C, Landi MT, Lang J, Lathrop GM, Lubiński J, Mackie RM, Molven A, Novaković S, Olsson H, Puig S, Puig-Butille JA, van der Stoep N, van Doorn R, van Workum W, Goldstein AM, Kanetsky PA, Pharoah PD, Demenais F, Hayward NK, Newton Bishop JA, Bishop DT, Iles MM; GenoMEL Consortium.

Int J Cancer. 2015 Mar 15;136(6):1351-60. doi: 10.1002/ijc.29099. Epub 2014 Aug 14.

28.

POT1 loss-of-function variants predispose to familial melanoma.

Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, Pooley KA, Pritchard AL, Tiffen JC, Petljak M, Palmer JM, Symmons J, Johansson P, Stark MS, Gartside MG, Snowden H, Montgomery GW, Martin NG, Liu JZ, Choi J, Makowski M, Brown KM, Dunning AM, Keane TM, López-Otín C, Gruis NA, Hayward NK, Bishop DT, Newton-Bishop JA, Adams DJ.

Nat Genet. 2014 May;46(5):478-481. doi: 10.1038/ng.2947. Epub 2014 Mar 30.

29.

Vitamin D and melanoma.

Field S, Davies J, Bishop DT, Newton-Bishop JA.

Dermatoendocrinol. 2013 Jan 1;5(1):121-9. doi: 10.4161/derm.25244. Review.

30.

Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom.

Harland M, Cust AE, Badenas C, Chang YM, Holland EA, Aguilera P, Aitken JF, Armstrong BK, Barrett JH, Carrera C, Chan M, Gascoyne J, Giles GG, Agha-Hamilton C, Hopper JL, Jenkins MA, Kanetsky PA, Kefford RF, Kolm I, Lowery J, Malvehy J, Ogbah Z, Puig-Butille JA, Orihuela-Segalés J, Randerson-Moor JA, Schmid H, Taylor CF, Whitaker L, Bishop DT, Mann GJ, Newton-Bishop JA, Puig S.

Hered Cancer Clin Pract. 2014 Nov 20;12(1):20. doi: 10.1186/1897-4287-12-20. eCollection 2014.

31.

MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study.

Cust AE, Goumas C, Vuong K, Davies JR, Barrett JH, Holland EA, Schmid H, Agha-Hamilton C, Armstrong BK, Kefford RF, Aitken JF, Giles GG, Bishop D, Newton-Bishop JA, Hopper JL, Mann GJ, Jenkins MA.

BMC Cancer. 2013 Sep 4;13:406. doi: 10.1186/1471-2407-13-406.

32.

Plasma osteopontin concentrations in patients with cutaneous melanoma.

Filia A, Elliott F, Wind T, Field S, Davies J, Kukalizch K, Randerson-Moor J, Harland M, Bishop DT, Banks RE, Newton-Bishop JA.

Oncol Rep. 2013 Oct;30(4):1575-80. doi: 10.3892/or.2013.2666. Epub 2013 Aug 8.

33.

Do vitamin A serum levels moderate outcome or the protective effect of vitamin D on outcome from malignant melanoma?

Field S, Elliott F, Randerson-Moor J, Kukalizch K, Barrett JH, Bishop DT, Newton-Bishop JA.

Clin Nutr. 2013 Dec;32(6):1012-6. doi: 10.1016/j.clnu.2013.04.006. Epub 2013 Apr 13.

PMID:
23669635
34.

An exploration of reported mortality from cutaneous squamous cell carcinoma using death certification and cancer registry data.

Rose RF, Boon A, Forman D, Merchant W, Bishop R, Newton-Bishop JA.

Br J Dermatol. 2013 Sep;169(3):682-6. doi: 10.1111/bjd.12388.

PMID:
23600487
35.

Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.

Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricalà C, Dalle S, Duval-Modeste AB, Ghiorzo P, Grammatico P, Harland M, Hayward NK, Hu HH, Jouary T, Martin-Denavit T, Ozola A, Palmer JM, Pastorino L, Pjanova D, Soufir N, Steine SJ, Stratigos AJ, Thomas L, Tinat J, Tsao H, Veinalde R, Tucker MA, Bressac-de Paillerets B, Newton-Bishop JA, Goldstein AM, Akslen LA, Molven A.

J Med Genet. 2013 Apr;50(4):264-70. doi: 10.1136/jmedgenet-2012-101455. Epub 2013 Feb 5. Erratum in: J Med Genet. 2014 Mar;51(3):214.

36.

Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk.

Liu H, Wang LE, Liu Z, Chen WV, Amos CI, Lee JE; Q-MEGA and AMFS Investigators; GenoMEL Investigators, Iles MM, Law MH, Barrett JH, Montgomery GW, Taylor JC, MacGregor S, Cust AE, Newton Bishop JA, Hayward NK, Bishop DT, Mann GJ, Affleck P, Wei Q.

Carcinogenesis. 2013 Apr;34(4):885-92. doi: 10.1093/carcin/bgs407. Epub 2013 Jan 4.

37.

Second primary melanomas on treatment with vemurafenib: reply from the authors.

Fearfield L, Newton-Bishop JA, Sinha R, Edmonds K, Gore ME, Larkin J.

Br J Dermatol. 2013 Apr;168(4):888-9. doi: 10.1111/bjd.12094. No abstract available.

PMID:
23066884
38.

Response to P. Autier and M. Boniol regarding our article--Relationship between sunbed use and melanoma risk in a large case-control study in the United Kingdom.

Elliott F, Barrett JH, Timothy Bishop D, Newton-Bishop JA.

Int J Cancer. 2013 Apr 15;132(8):1960-1. doi: 10.1002/ijc.27847. Epub 2012 Oct 12. No abstract available.

39.

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.

Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L.

Br J Dermatol. 2012 Nov;167(5):987-94. doi: 10.1111/bjd.12010. Review.

PMID:
22913467
40.

Pathway-based analysis of a melanoma genome-wide association study: analysis of genes related to tumour-immunosuppression.

Schoof N, Iles MM, Bishop DT, Newton-Bishop JA, Barrett JH; Genomel Consortium.

PLoS One. 2011;6(12):e29451. doi: 10.1371/journal.pone.0029451. Epub 2011 Dec 27.

41.

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.

Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM.

Nature. 2011 Nov 13;480(7375):99-103. doi: 10.1038/nature10630.

42.

Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma.

Storr SJ, Safuan S, Mitra A, Elliott F, Walker C, Vasko MJ, Ho B, Cook M, Mohammed RA, Patel PM, Ellis IO, Newton-Bishop JA, Martin SG.

Mod Pathol. 2012 Apr;25(4):493-504. doi: 10.1038/modpathol.2011.182. Epub 2011 Nov 11.

43.

Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3.

Macgregor S, Montgomery GW, Liu JZ, Zhao ZZ, Henders AK, Stark M, Schmid H, Holland EA, Duffy DL, Zhang M, Painter JN, Nyholt DR, Maskiell JA, Jetann J, Ferguson M, Cust AE, Jenkins MA, Whiteman DC, Olsson H, Puig S, Bianchi-Scarrà G, Hansson J, Demenais F, Landi MT, Dębniak T, Mackie R, Azizi E, Bressac-de Paillerets B, Goldstein AM, Kanetsky PA, Gruis NA, Elder DE, Newton-Bishop JA, Bishop DT, Iles MM, Helsing P, Amos CI, Wei Q, Wang LE, Lee JE, Qureshi AA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Han J, Hopper JL, Trent JM, Brown KM, Martin NG, Mann GJ, Hayward NK.

Nat Genet. 2011 Oct 9;43(11):1114-8. doi: 10.1038/ng.958.

44.

The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate.

Davies JR, Chang YM, Snowden H, Chan M, Leake S, Karpavicius B, Haynes S, Kukalizch K, Randerson-Moor J, Elliott F, Barth J, Kanetsky PA, Harland M, Bishop DT, Barrett JH, Newton-Bishop JA.

Cancer Causes Control. 2011 Oct;22(10):1471-82. doi: 10.1007/s10552-011-9827-3. Epub 2011 Aug 19.

45.

Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia.

Mitra A, Gooi J, Darling J, Newton-Bishop JA.

J Am Acad Dermatol. 2011 Sep;65(3):676-677. doi: 10.1016/j.jaad.2010.06.060. No abstract available.

PMID:
21839336
46.

Relationship between sunbed use and melanoma risk in a large case-control study in the United Kingdom.

Elliott F, Suppa M, Chan M, Leake S, Karpavicius B, Haynes S, Barrett JH, Bishop DT, Newton-Bishop JA.

Int J Cancer. 2012 Jun 15;130(12):3011-3. doi: 10.1002/ijc.26347. Epub 2011 Aug 30. No abstract available.

47.

The determinants of periorbital skin ageing in participants of a melanoma case-control study in the U.K.

Suppa M, Elliott F, Mikeljevic JS, Mukasa Y, Chan M, Leake S, Karpavicius B, Haynes S, Bakker E, Peris K, Barrett JH, Bishop DT, Newton Bishop JA.

Br J Dermatol. 2011 Nov;165(5):1011-21. doi: 10.1111/j.1365-2133.2011.10536.x.

48.

Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.

van der Ploeg AP, van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, Newton-Bishop JA, Cook M, van der Ploeg IM, Nieweg OE, van den Hout MF, van Leeuwen PA, Voit CA, Cataldo F, Testori A, Robert C, Hoekstra HJ, Verhoef C, Spatz A, Eggermont AM.

J Clin Oncol. 2011 Jun 1;29(16):2206-14. doi: 10.1200/JCO.2010.31.6760. Epub 2011 Apr 25.

PMID:
21519012
49.

Melanoma and vitamin D.

Field S, Newton-Bishop JA.

Mol Oncol. 2011 Apr;5(2):197-214. doi: 10.1016/j.molonc.2011.01.007. Epub 2011 Feb 3. Review.

50.

Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK.

Cust AE, Harland M, Makalic E, Schmidt D, Dowty JG, Aitken JF, Agha-Hamilton C, Armstrong BK, Barrett JH, Chan M, Chang YM, Gascoyne J, Giles GG, Holland EA, Kefford RF, Kukalizch K, Lowery J, Randerson-Moor JA, Schmid H, Taylor CF, Whitaker L, Hopper JL, Newton-Bishop JA, Mann GJ, Bishop DT, Jenkins MA.

J Med Genet. 2011 Apr;48(4):266-72. doi: 10.1136/jmg.2010.086538. Epub 2011 Feb 15.

PMID:
21325014

Supplemental Content

Loading ...
Support Center